Latest Breaking News On - Net product revenue - Page 3 : comparemela.com

Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update

Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesPark cityBen shannonChris brinzeyDonald notmanAntony mattessichSanten incMidcap financialOcular therapeutix incExchange commissionNet product revenueRepresenting growthCash runway now forecastedTwo planned pivotal clinical trialsNon proliferative diabetic retinopathyBegan pilot repeat dose

Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

– Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 2023.

United statesSouth koreaKyongsang buktoUnited kingdomRichard paulsonTrademark officeDrug administrationEuropean hematology associationPrnewswire karyopharm therapeutics incExchange commissionSelective inhibitor of nuclear exportMenarini groupKaryopharm selective inhibitor of nuclear exportCompany ongoing pivotal phaseAmerican society of clinical oncologyInformation department

Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results

/PRNewswire/ Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that.

United statesSouth koreaCh ungch ong buktoCarl spanaFosun pharmaKwangdong pharmaceuticalsDrug administrationPrnewswire palatin technologies incExchange commissionPalatin technologies incSecurities exchangeGross product revenueNet product revenuePreliminary vyleesiHypoactive sexual desire disorderSecurities act

Alimera Sciences Reports First Quarter 2023 Results

Consolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022Global End User Demand Up 14% vs. First Quarter of 2022 Financial Results and Corporate Update Conference Call Cancelled . | May 15, 2023

Switzerland generalScott gordonJules abrahamMichael kasetaAdam morganRick eiswirthCapital partnersAlimera sciencesExchange commissionAlimera sciences incGlobenewswire incConsolidated net revenueCorporate update conference callChief executivePreferred stockFirst quarter highlights

Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor. | May 12, 2023

United statesDarren clineChristina tartagliaMichaelw kalbAdrian adamsMelyssa weibleImpel pharmaceuticals incAmerican academy of neurologyExchange commissionCincor pharma incElixir health public relationsImpel pharmaceuticalsCompany developmentsDevelopment rd expensesNet product revenueHost investor conference call today